Study Evaluating the Safety and Efficacy of KITE-363 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Status:
Recruiting
Trial end date:
2041-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of Phase 1a of the study is to evaluate the safety of KITE-363 in
participants with relapsed and/or refractory (r/r) B-cell lymphoma and to determine the dose
level(s) for Phase 1b dose expansion.
The primary objective of Phase 1b of the study is to evaluate the efficacy of KITE-363 in
participants with r/r B-cell lymphoma as measured by the objective response rate (ORR)
defined as complete response (CR) plus partial response (PR) rates.